New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Prognosis of increasing percentages of lesional body surface area in early stage mycosis fungoides.
À¶Ý®ÊÓÆµ
Prognosis of increasing percentages of lesional body surface area in early stage mycosis fungoides. Journal of the European Academy of Dermatology and Venereology : JEADV Kersten, J. M., Ottevanger, R., Quint, K. D., Vermeer, M. H., Goeman, J. J., Kim, Y., Evison, F., Scarisbrick, J. J., Willemze, R. 2025Abstract
Early-stage mycosis fungoides (MF) is often an indolent disease with a favourable prognosis, though 25% progress to advanced stages. Patients with =10% body surface area (BSA) involvement have a worse prognosis than those with <10%, but the impact of other BSA levels remains unclear.This study aimed to determine whether additional BSA cut-off points higher than 10% provide additional prognostic information.This study included 401 patients with early-stage MF of the Leiden University Medical Centre and a validation cohort of 602 patients from the PROCLIPI database. Different percentages of lesional BSA were analysed both in the total groups and in subgroups of patients with only patch-stage disease or with patch-plaques-stage disease, and correlated with survival.Both cohorts showed a progressive and gradual decline in overall survival (OS) with each 10% increase in BSA, reaching a 5-year OS below 50% (LUMC) or 70% (PROCLIPI) for BSA =40%. In both cohorts, patients with a BSA of 10%-39% had a significantly worse OS than those with a BSA of less than 10%, but a significantly better OS than those with =40%. These differences in OS were only found in patients with patches and plaques and not in patients with only patches.An additional cut-off point of 40% involved BSA has prognostic significance in patients with early patch/plaque-stage MF and may be included in future updates of the clinical staging system. In these patients, systemic therapies should be considered.
View details for
View details for